A Phase 3 interventional study of octreotide capsules and Matching placebo in Acromegaly, sponsored by Chiasma, Inc.. Status unknown at 60 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-23.
Sponsored by Chiasma, Inc. (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.
Among the 25 studies testing octreotide in Acromegaly, this one is the 13th largest by enrollment, is the only one that started in 2017, is one of 12 in phase 3, and was the 21st registered.
202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.
Browse Acromegaly studies →1 of the 25 studies testing octreotide in Acromegaly is open now. Recruiting first, the newest first:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Ages 18–80
Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is above the median of 43 across 115 interventional studies indexed under Acromegaly.
Median enrollment 56 across the 25 interventional studies. Of the 22 that completed or were terminated, 7 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chiasma, Inc., one of the names counted as Chiesi Farmaceutici S.p.A.. Under that name alone:
Chiasma, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Chiesi Farmaceutici S.p.A. has 3 studies filed under Acromegaly — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing octreotide in Acromegaly, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated maintenance of biochemical response up to 13 months in the majority of patients with acromegaly previously managed with somatostatin analog injections (reference below).
This is a double blind, randomized study that assesses the efficacy and safety of octreotide capsules vs. placebo. Eligible acromegaly patients, treated with injectable somatostatin analogs, who are biochemically controlled and have prior evidence of active disease, will be randomized to receive either octreotide capsules or placebo for up to 36 weeks. At the end of this double blind, placebo controlled period, eligible patients will receive octreotide capsules in an open-labeled extension for at least one year. Patients failing to respond (per protocol), to oral treatment, (either placebo or octreotide capsules), will be rescued with the standard of care and upon meeting the eligibility criteria could also enroll into the long term extension with octreotide capsules.
This study received agreement from the FDA, under a special protocol assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Octreotide capsules
Drug: octreotide capsules
Matching placebo capsules
Drug: Matching placebo
octreotide capsules 40 mg/day, 60 mg/day, 80 mg/day (individual dose titration)
Also known as: MYCAPSSA
Matching placebo capsules
Also known as: Placebo
Number of Patients Who Maintain Their Biochemical Response at the End of the Double Blind Placebo Controlled (DPC) Period.
Maintenance of response was defined by using the average IGF-1 level of the last 2 available assessments in the DPC period. If the average IGF-1 is ≤ 1×ULN, a patient was classified as a responder (i.e., maintained their biochemical response). If the average IGF-1 is \> 1×ULN, a patient was classified as a non-responder. Patients who discontinue study medication during the DPC period for any reason was classified as non-responders for the primary analysis, regardless of their IGF-1 values.
Time frame: Week 36
Number of Patients Who Maintain Growth Hormone (GH) Response at the End of the Double Blind Placebo Controlled Period
Maintenance of GH response was defined as having mean Growth Hormone (5 measurements 30 minutes apart) \< 2.5 ng/mL at the end of the double blind placebo controlled period, out of those who were responders on Somatostatin Receptor Ligands (SRLs) injections at Screening.
Time frame: Week 36
Number of Patients Who Begin Rescue Treatment
Number of Patients who Began Rescue Treatment Prior to and Including Week 36
Time frame: Week 36
| Milestone | Octreotide Capsules | Matching Placebo |
|---|---|---|
| Started | 28 | 28 |
| Completed | 28 | 28 |
| Not completed | 0 | 0 |
Maintenance of response was defined by using the average IGF-1 level of the last 2 available assessments in the DPC period. If the average IGF-1 is ≤ 1×ULN, a patient was classified as a responder (i.e., maintained their biochemical response). If the average IGF-1 is \> 1×ULN, a patient was classified as a non-responder. Patients who discontinue study medication during the DPC period for any reason was classified as non-responders for the primary analysis, regardless of their IGF-1 values.
| Participants | Octreotide Capsules | Matching Placebo |
|---|---|---|
| Number of Patients Who Maintain Their Biochemical Response at the End of the Double Blind Placebo Controlled (DPC) Period. | 16 | 5 |
Maintenance of GH response was defined as having mean Growth Hormone (5 measurements 30 minutes apart) \< 2.5 ng/mL at the end of the double blind placebo controlled period, out of those who were responders on Somatostatin Receptor Ligands (SRLs) injections at Screening.
| Participants | Octreotide Capsules | Placebo |
|---|---|---|
| Number of Patients Who Maintain Growth Hormone (GH) Response at the End of the Double Blind Placebo Controlled Period | 21 | 7 |
Number of Patients who Began Rescue Treatment Prior to and Including Week 36
| Participants | Octreotide Capsules | Placebo |
|---|---|---|
| Number of Patients Who Begin Rescue Treatment | 7 | 19 |
Collected over 1 year, 10 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Octreotide Capsules | 0/28 (0%) | 2/28 (7.1%) | 28/28 (100%) |
| Matching Placebo | 0/28 (0%) | 1/28 (3.6%) | 27/28 (96.4%) |
| Event | Octreotide Capsules | Matching Placebo |
|---|---|---|
| Cholecystitis acuteHepatobiliary disorders | 1/28 | 0/28 |
| Joint dislocationInjury, poisoning and procedural complications | 0/28 | 1/28 |
| ArthritisMusculoskeletal and connective tissue disorders | 1/28 | 0/28 |
| Event | Octreotide Capsules | Matching Placebo |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/28 | 16/28 |
| HeadacheNervous system disorders | 4/28 | 9/28 |
| DiarrhoeaGastrointestinal disorders | 8/28 | 6/28 |
| FatigueGeneral disorders | 2/28 | 7/28 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 6/28 | 7/28 |
| NauseaGastrointestinal disorders | 6/28 | 3/28 |
| Abdominal discomfortGastrointestinal disorders | 4/28 | 3/28 |
| ConstipationGastrointestinal disorders | 3/28 | 4/28 |
| VomitingGastrointestinal disorders | 4/28 | 0/28 |
| Peripheral swellingGeneral disorders | 3/28 | 4/28 |
| Age, Continuous(years) | Octreotide Capsules | Matching Placebo | Total |
|---|---|---|---|
| Age | 55.3 ± 11.97 | 54.2 ± 10.96 | 54.7 ± 11.38 |
| Sex: Female, Male(Participants) | Octreotide Capsules | Matching Placebo | Total |
|---|---|---|---|
| Female | 16 | 14 | 30 |
| Male | 12 | 14 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Octreotide Capsules | Matching Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 3 |
| Not Hispanic or Latino | 28 | 25 | 53 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Octreotide Capsules | Matching Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 27 | 24 | 51 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Baseline average Insulin-like Growth Factor 1 (IGF-1) (categorical)(Participants) | Octreotide Capsules | Matching Placebo | Total |
|---|---|---|---|
| IGF≤ 1 Upper Limit of Normal (ULN) | 27 | 23 | 50 |
| IGF > 1 to < 1.3 ULN | 1 | 5 | 6 |
| IGF≥ 1.3 ULN | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2017 to primary completion in Jun 2019, 21 months.
Results were first posted in Oct 2020, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Octreotide